Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS010 Gene Therapy for LHON (REVERSE)
NCT02652780Phase 3Completed
- Sponsor
- GenSight Biologics
- Start
- Jan 2016
- Primary completion
- Jan 2018
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 5
01
Overview
A Phase 3 trial of lenadogene nolparvovec in Leber hereditary optic neuropathy (LHON), sponsored by GenSight Biologics. Started Jan 2016; status: completed.
02
Drugs
lenadogene nolparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT02652780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652780.